Form D · Biotechnology
Zivo Bioscience, Inc.
Bloomfield Hills, MI · CIK 0001101026
Offering snapshot reported Jul 17, 2023 · SEC filing
- Reported sold
- $4M Offering amount: $4M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 17, 2023 | Initial | $3,999,960 | No comparison | 1 | SEC filing |
| May 15, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Oct 14, 2016 | Initial | $1,250,000 | No comparison | 6 | SEC filing |
| Mar 28, 2014 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Dec 24, 2013 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Dec 23, 2013 | Initial | $375,000 | No comparison | 1 | SEC filing |
| Aug 26, 2013 | Initial | $132,000 | No comparison | 5 | SEC filing |
| Aug 12, 2013 | Initial | $325,000 | No comparison | 5 | SEC filing |
| Jan 7, 2013 | Initial | $35,000 | No comparison | 1 | SEC filing |
| Dec 27, 2012 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Dec 26, 2012 | Initial | $140,000 | No comparison | 1 | SEC filing |
| Jul 27, 2012 | Initial | $62,500 | No comparison | 1 | SEC filing |
| Jul 27, 2012 | Initial | $62,500 | No comparison | 1 | SEC filing |
| May 24, 2012 | Initial | $300,000 | No comparison | 1 | SEC filing |
| May 14, 2012 | Amendment | $1,025,000 | $250,000vs Apr 17, 2012 | 1 | SEC filing |
| Apr 17, 2012 | Amendment | $775,000 | $75,000vs Mar 26, 2012 | 1 | SEC filing |
| Apr 10, 2012 | Amendment | $395,708 | $63,708vs Feb 10, 2012 | 1 | SEC filing |
| Mar 26, 2012 | Amendment | $700,000 | $100,000vs Dec 12, 2011 | 1 | SEC filing |
| Feb 13, 2012 | Amendment | $332,000 | $0vs Feb 10, 2012 | 1 | SEC filing |
| Feb 10, 2012 | Amendment | $332,000 | $54,000vs Dec 9, 2011 | 1 | SEC filing |
| Dec 12, 2011 | Initial | $600,000 | No comparison | 1 | SEC filing |
| Dec 9, 2011 | Initial | $278,000 | No comparison | 1 | SEC filing |
| Nov 14, 2011 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Sep 2, 2011 | Amendment | $290,500 | $34,000vs Jul 28, 2011 | 7 | SEC filing |
| Jul 28, 2011 | Amendment | $256,500 | $100,000vs Jun 30, 2011 | 7 | SEC filing |
| Jun 30, 2011 | Amendment | $156,500 | $14,000vs Jun 10, 2011 | 7 | SEC filing |
| Jun 10, 2011 | Amendment | $142,500 | $20,000vs Apr 21, 2011 | 7 | SEC filing |
| Jun 1, 2011 | Amendment | $1,717,128 | $10,000vs Mar 3, 2011 | 43 | SEC filing |
| Apr 21, 2011 | Amendment | $122,500 | $10,000vs Feb 11, 2011 | 7 | SEC filing |
| Mar 3, 2011 | Amendment | $1,707,128 | $80,000vs Feb 14, 2011 | 43 | SEC filing |
| Feb 14, 2011 | Amendment | $112,500 | $0vs Feb 11, 2011 | 6 | SEC filing |
| Feb 14, 2011 | Amendment | $1,627,128 | $0vs Feb 1, 2011 | 43 | SEC filing |
| Feb 11, 2011 | Initial | $112,500 | No comparison | 6 | SEC filing |
| Feb 1, 2011 | Amendment | $1,627,128 | $80,000vs Oct 1, 2010 | 43 | SEC filing |
| Oct 1, 2010 | Amendment | $1,547,128 | $65,000vs Sep 8, 2010 | 42 | SEC filing |
| Sep 8, 2010 | Amendment | $1,482,128 | $25,000vs Aug 6, 2010 | 42 | SEC filing |
| Aug 6, 2010 | Amendment | $1,457,128 | $50,000vs Jul 21, 2010 | 41 | SEC filing |
| Jul 21, 2010 | Amendment | $1,407,128 | $17,500vs Jun 3, 2010 | 39 | SEC filing |
| Jun 3, 2010 | Amendment | $1,389,628 | $100,000vs May 20, 2010 | 38 | SEC filing |
| May 20, 2010 | Amendment | $1,289,628 | $50,000vs Apr 28, 2010 | 37 | SEC filing |
| Apr 28, 2010 | Initial | $675,000 | No comparison | 1 | SEC filing |
| Apr 28, 2010 | Amendment | $1,239,628 | $155,000vs Apr 6, 2010 | 35 | SEC filing |
| Apr 6, 2010 | Amendment | $1,084,628 | $101,666vs Mar 16, 2010 | 31 | SEC filing |
| Mar 16, 2010 | Amendment | $982,962 | $377,462vs Feb 19, 2010 | 26 | SEC filing |
| Mar 16, 2010 | Amendment | $982,962 | $0vs Mar 16, 2010 | 26 | SEC filing |
| Feb 19, 2010 | Amendment | $605,500 | $36,000vs Feb 4, 2010 | 14 | SEC filing |
| Feb 4, 2010 | Amendment | $569,500 | $45,500vs Dec 17, 2009 | 11 | SEC filing |
| Dec 17, 2009 | Amendment | $524,000 | $24,000vs Nov 19, 2009 | 10 | SEC filing |
| Nov 19, 2009 | Amendment | $500,000 | $165,000vs Oct 13, 2009 | 10 | SEC filing |
| Oct 13, 2009 | Amendment | $335,000 | $130,000vs Sep 21, 2009 | 3 | SEC filing |
| Sep 21, 2009 | Initial | $205,000 | No comparison | 3 | SEC filing |
| Mar 7, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 7, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 8, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 11, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $280K
- Finders' fees
- $0
- Form D file number
- 021-487144
Warrants to purchase shares of common stock were issued for no separate consideration in connection with a sale of common stock and prefunded warrants to an investor. Excludes potential proceeds totaling up to $8,389,528 to be received upon exercise.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLC | 120708 |
Source: Form D, filed Jul 17, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Howard Baer | Promoter |
| Allison A. Cornell | Director |
| Thomas Cox | Director |
| Janet Crance | Director, Executive |
| John Crissman | Director |
| Andrew A Dahl | Executive |
| John Gorman | Director |
| Christopher D. Maggiore | Director |
| Chris Maggiore | Director |
| Christophe Maggiore | Director |
| Keith R. Marchiando | Executive |
| Nola E. Masterson | Director |
| John B. Payne | Executive |
| Philip Rice | Director, Executive |
| Phillip Rice | Director, Executive |
| Philip Marshall Rice Ii | Director, Executive |
| Robert Rondeau | Director |
| Peter Vitulli | Executive |
| Steven Warner | Director |
| Brian Young | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
21 E. Long Lake Road Suite 100
Bloomfield Hills, MI, 48304
Bloomfield Hills, MI, 48304